Table 1 Characteristics of eligible studies included in meta-analysis
From: Pulmonary function in children post -SARS-CoV-2 infection: a systematic review and meta-analysis
Name | Study design | Sample size | Time from infection/recovery to PFT (month) | Disease severity | Asthma history | FEV1 (%) | FVC (%) | FEV1/FVC | FEF25-75 (%) | DLCO (%) |
|---|---|---|---|---|---|---|---|---|---|---|
Palacios (USA) | Cohort | 82 | 6.7 (4.9, 8.6) | All types | Not Excluded | 104 (97–111) | 104 ± 13 | NR | 96 (102–126) | 118 ± 17 |
Ipek (Turkey) | Cross sectional | 34 | 49 (36)* | All types | Excluded | 98.67 ± 14.93 | 94.21 ± 13.68 | 101.06 ± 24.89 | 101.85 ± 24.89 | NR |
Ozturk (Turkey) | Cross sectional | 50 | 3 | All types | Excluded | 105.18 ± 15.92 | 110.38 ± 12.33 | 94.18 ± 8.76 | 95.82 ± 26.31 | 89.65 ± 8.76 |
Chiara (Italy) | Observational | 61 | 10 ± 4 | Asymptomatic | Excluded | 98.38 (94.38–104.39) | 93.35 (89.56–103.56) | 105.34 (100.06–107.46) | 105.26 (92.35–117.33) | NR |
Bottino (Italy) | Cross sectional | 16 | 67 (49–91)* | Asymptomatic | Excluded | 96 (94–102) | 95 (87–100) | 92 (87–97) | NR | 119 (111–132) |
Dobkin (USA) | Cohort | 29 | 6 weeks or more | All types | Not Excluded | 107 ± 12 | 110 ± 16 | 86 ± 8 | 100 ± 23 | 95 ± 17 |
Knoke (Germany)+ | Cross sectional | 73 | 2.59 (0.4, 6) | All types | Not Excluded | 0.3 ± 1.04 | −0.21 ± 1.06 | - | - | 2.03 ± 2.35 |
Boguslawski (Poland) + | Observational | 41 | Up to 6 months | All types | Not Excluded | −0.76 (− 1.36,2.01) | 0.49 (− 0.5,1.7) | 0.04 (− 1.05, 0.64) | - | 0.18 (− 0.84,0.61) |